Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models
A P Tkachuk, V A Gushchin, V D Potapov, A V Demidenko, V G Lunin, A L Gintsburg, A P Tkachuk, V A Gushchin, V D Potapov, A V Demidenko, V G Lunin, A L Gintsburg
Abstract
New innovative vaccines are highly needed to combat the global threat posed by tuberculosis. Efficient components-antigens and adjuvants-are crucial for development of modern recombinant TB vaccines. This study describes a new vaccine (GamTBvac) consisting of two mycobacterial antigen fusions (Ag85A and ESAT6-CFP10)-with dextran-binding domain immobilized on dextran and mixed with an adjuvant consisting of DEAE-dextran core, and with CpG oligodeoxynucleotides (TLR9 agonists). GamTBvac and its components were assessed for immunogenicity and protective efficacy in GamTBvac-prime/boost and BCG-prime/ GamTBvac-boost in murine and guinea pig TB models. Results show that in both infectious models, GamTBvac has a strong immunogenicity and significant protective effect against Mycobacterium tuberculosis strain H37Rv under aerosol and intravenous challenges. GamTBvac showed a particularly strong protective effect as a BCG booster vaccine.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- WHO, Global Tuberculosis Report 2016. 21th edition France: World Health Organisation; 2016;214
- Andersen P, Urdahl KB. TB vaccines; promoting rapid and durable protection in the lung. Curr Opin Immunol. Elsevier Ltd; 2015;35: 55–62.
- Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global Epidemiology of Tuberculosis. Cold Spring harb Perspec Med. 2015; 1–18.
- Karp CL, Wilson CB, Stuart LM. Tuberculosis vaccines: Barriers and prospects on the quest for a transformative tool. Immunol Rev. 2015;264: 363–381. 10.1111/imr.12270
- Andersen P, Doherty TM. The success and failure of BCG—implications for a novel tuberculosis vaccine. Nature reviews Microbiology. 2005; 3(8):656–62. 10.1038/nrmicro1211
- Pang Y, Zhao A, Cohen C, Kang W, Lu J, Wang G, et al. Current status of new tuberculosis vaccine in children. Hum Vaccin Immunother. 2016;5515: 1–11.
- Fine PE Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346: 1339–1345. S0140-6736(95)92348-9.
- Nguipdop-Djomo P., Heldal E., Rodrigues L. C., Abubakar I., & Mangtani P. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: A retrospective population-based cohort study. The Lancet Infectious Diseases 2016;16(2): 219–226. 10.1016/S1473-3099(15)00400-4
- Skeiky YAW, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine. 2010;28: 1084–1093. 10.1016/j.vaccine.2009.10.114
- Rodrigues LC, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005;366(9493):1290–5. 10.1016/S0140-6736(05)67145-0
- Frick M. The Tuberculosis Vaccines Pipeline: A New Path to the Same Destination? HIV, HCV & TB Pipeline Report (Treatment Action Group). HIV& TB (2015). July 2015. . Cited 25 August 2016.
- Agger EM. Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates. Adv Drug Deliv Rev. Elsevier B.V.; 2015;
- Carpenter C, Sidney J, Kolla R, Nayak K, Tomiyama H, Tomiyama C, et al. A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis. Elsevier Ltd; 2015;95: 713–721.
- Xin Q, Niu H, Li Z, Zhang G, Hu L, Wang B, et al. Subunit Vaccine Consisting of Multi-Stage Antigens Has High Protective Efficacy against Mycobacterium tuberculosis Infection in Mice. PLoS One. 2013;8: 1–12.
- Niu H, Peng J, Bai C, Liu X, Hu L, Luo Y, et al. Multi-stage tuberculosis subunit vaccine candidate LT69 provides high protection against Mycobacterium tuberculosis infection in mice. PLoS One. 2015;10: 1–11.
- Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN. The importance of adjuvant formulation in the development of a TB vaccine. J Immunol. 2012;188: 2189–2197. 10.4049/jimmunol.1102696
- Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov D V., Shmarov MM, Dolzhikova I V., et al. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses. PLoS One. 2016;11: e0155650 10.1371/journal.pone.0155650
- Knudsen NPH, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, et al. Different human vaccine adjuvants promote distinct antigen- independent immunological signatures tailored to different pathogens. 2016; 1–13.
- Cordeiro AS, Alonso MJ, de la Fuente M. Nanoengineering of vaccines using natural polysaccharides. Biotechnol Adv. Elsevier B.V.; 2015;33: 1279–1293.
- Cox J.C., Coulter A.R. Adjuvant—a classification and rewiew of their modes of action. Vaccine. 1997;15 (3) 248–256.
- Ershova AS, Gra OA, Lyaschuk AM, Grunina TM, Tkachuk AP, Bartov MS, et al. Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice. BMC Infect Dis. 2016;16: 544 10.1186/s12879-016-1884-5
- Tkachuk A., Lunin V., Karyagina A., Gintsburg A. Problems and prospects of development of the subunit TB vaccine. J Acquir Immune Defic Syndr 2014; 65(Suppl 2): 43.
- Cumming G, Fidler F, Vaux DL. Error bars in experimental biology. J Cell Biol. 2007;177: 7–11. 10.1083/jcb.200611141
- Olsen AW, Pinxteren L, Okkels LM, Rasmussen PB, Andersen P. Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6. Microbiology. 2001;69: 2773–2778.
- Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A, Kritsch C, et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine. 2006;24: 5452–5460. 10.1016/j.vaccine.2006.03.072
- Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, et al. Safety and immunogenicity of h1/ic31h, an adjuvanted tb subunit vaccine, in hiv-infected adults with cd4+ lymphocyte counts greater than 350 cells/mm3: A phase ii, multi-centre, double-blind, randomized, placebo-controlled trial e114602. PLoS One. 2014;9: 1–19.
- Geldenhuys H, Mearns H, Miles DJC, Tameris M, Hokey D, Shi Z, et al. The tuberculosis vaccine H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine. Elsevier Ltd; 2015;33: 3592–3599.
- Aagaard C, Hoang T, Dietrich J, Cardona P-J, Izzo A, Dolganov G, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. Nature Publishing Group; 2011;17: 189–194.
- Billeskov R, Elvang TT, Andersen PL, Dietrich J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One. 2012;7.
- Woodworth JS, Cohen SB, Moguche AO, Plumlee CR, Agger EM, Urdahl KB, et al. Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung. Mucosal Immunol. Nature Publishing Group; 2016;
- Li W, Li M, Deng G, Zhao L, Liu X, Wang Y. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice. Mol Med Rep. 2015;12: 3073–3080. 10.3892/mmr.2015.3770
- Chen YY, Lin CW, Huang WF, Chang JR, Su IJ, Hsu CH, et al. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis. J Microbiol Immunol Infect. Elsevier Taiwan LLC; 2014; 1–7.
- Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, et al. Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial. EBioMedicine. The Authors; 2016;7: 278–286.
- Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PEM, et al. Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials. Clin Infect Dis. 2014;58: 470–480. 10.1093/cid/cit790
- Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne J, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Gue rin vaccination against tuberculosis. Health Technol Assess (Rockv). 2013;17: 1–4.
- Aronson NE, Santosham Mathuram, Comstock GW, Howard RS, Moulton LH, Everett R. Rhoades, et al. Long-term Efficacy of BCG Vaccine. 2004;291: 2086–2091.
- Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, et al. Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial. EBioMedicine. The Authors; 2016;7: 278–286.
- Mohamed W, Domann E, Chakraborty T, Mannala G, Lips KS, Heiss C, et al. TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress. BMC Microbiol. BMC Microbiology; 2016; 1–8.
- Pustylnikov S, Sagar D, Jain P, Khan ZK. Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran. 2014;17: 371–392.
- Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA et al.: Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021–1028. 10.1016/S0140-6736(13)60177-4
- Beverley P: TB vaccine failure was predictable. Nature. 2013;503:p469;
- van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine. 2010;28: 3571–3581. 10.1016/j.vaccine.2010.02.094
- van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine. Elsevier Ltd; 2011;29: 2100–2109.
- Van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009;180: 49–58. 10.1164/rccm.200811-1704OC
- Frick B. M. The Tuberculosis Prevention Pipeline. 2016:143–162.
- Millington KA, Fortune SM, Low J, Garces A, Hingley-Wilson SM, et al. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 2011;108: 5730–5735. 10.1073/pnas.1015153108
Source: PubMed